The US FDA has issued new guidance on ways to expand development of non-opioid treatment options for chronic pain.

Journavx (suzetrigine) 50 mg oral tablets, the first-in-class non-opioid analgesic for moderate to severe acute pain, was ...

The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid ...

By Stephanie Brown HealthDay ReporterWEDNESDAY, Sept. 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration ...

Manufacturers shouldn't try to address this guidance without specific feedback and support from cybersecurity experts.c ...

U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement ...

Advisory committee meetings help FDA scientists make decisions and increase public understanding of drug regulation, and ...

In today's Morning Rounds newsletter, NIH is finally spending down its coffers, FDA eyes tighter regulations on chatbots for ...

The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters ...

The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and ...

Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing ...